Myorenova is developing InjectaGel — a field-deployable injectable scaffold system designed to accelerate recovery from acute skeletal muscle injuries.
Acute skeletal muscle strains — common in military, sports, and occupational settings — affect millions annually. Current standard of care relies on rest, ice, compression, and elevation. There is no FDA-cleared biologic or device that actively promotes muscle tissue regeneration.
The result: prolonged recovery timelines, re-injury risk, and long-term functional deficits — especially in high-demand populations where rapid return to duty or play is critical.
InjectaGel is a field-deployable muscle regeneration system combining a proprietary bioactive hydrogel scaffold with a spring-driven dual-barrel autoinjector — engineered for use outside of clinical settings.
Myorenova was founded by a multidisciplinary team of biomedical engineers with deep expertise across materials science, mechanical design, and life sciences commercialization.
We are actively seeking pre-seed investment, research partnerships, and clinical collaborators. Reach out to learn more about InjectaGel and our development roadmap.